# A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

> **NCT02338349** · PHASE1 · COMPLETED · sponsor: **Stemline Therapeutics, Inc.** · enrollment: 57 (actual)

## Conditions studied

- Advanced ER+, HER2-Negative Breast Cancer

## Interventions

- **DRUG:** Elacestrant

## Key facts

- **NCT ID:** NCT02338349
- **Lead sponsor:** Stemline Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2019-09
- **Final completion:** 2020-04
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2022-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02338349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02338349, "A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02338349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*